Table 3 Univariate logistic regression model for predictors for antibody response after second vaccination (patients only).

From: Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients

Variable

Patients with antibody responsea

(n = 6)

Patients without antibody responsea

(n = 11)

Odds ratio

(95% confidence interval)

p Value

Age in years, median (IQR)

27 (25–38.5)

43 (26–55)

0.96 (0.88–1.03)

0.250

BMI, median (IQR)

23.3 (19.4–31.5)

27.8 (24–31.5)

0.94 (0.76–1.09)

0.417

Female gender

4 (66.7%)

2 (18.2%)

6.84 (0.94–67.18)

0.058

AML

5 (83.3%)

7 (63.3%)

2.20 (0.29–26.79)

0.459

Myeloablative conditioning regimen

4 (66.7%)

4 (36.4%)

3.00 (0.45–24.16)

0.257

Related donor

5 (83.3%)

4 (36.4%)

6.11 (0.83–75.72)

0.077

Prior acute GvHD

1 (16.7%)

3 (27.3%)

0.66 (0.05–5.49)

0.709

Chronic GvHD

4 (66.7%)

8 (72.7%)

0.74 (0.10–5.94)

0.768

Any immunosuppressive medication

4 (66.7%)

7 (63.6%)

1.08 (0.16–8.42)

0.938

EBMT score >2

3 (50%)

8 (72.7%)

0.41 (0.05–2.86)

0.366

T cell count/µl, median (IQR)

1220 (1144–1513)

766 (576–1115)

1.00 (1.00–1.00)

0.196

T cell reconstitutionb

5 (83.3%)

3 (27.3%)

8.90 (1.18–115.07)

0.033

CD4+ cell count/µl, median (IQR)

456 (380–544)

315 (257–387)

1.01 (1.00–1.03)

0.019

 CD4+CD45RO+ cells in %, median (IQR)

52.9 (47.2–71)

64.5 (45.6–73.7)

0.99 (0.94–1.05)

0.755

 CD4+CD45RA+ cells in %, median (IQR)

26.5 (11.9–33.9)

17.8 (5.8–26.2)

1.03 (0.95–1.12)

0.474

CD8+ cell count/µl, median (IQR)

603 (476–1141)

340 (267–758)

1.00 (1.00–1.00)

0.614

CD4/CD8 ratio, median (IQR)

0.76 (0.33–1.15)

0.96 (0.42–1.16)

0.67 (0.08–4.59)

0.679

B cell count/µl, median (IQR)

358 (145–454)

380 (129–592)

0.999 (1.00–1.00)

0.584

 Memory B cells in %, median (IQR)

10.7 (6.65–15.43)

5.9 (4.3–14.55)

1.10 (0.89–1.13)

0.866

IgG level in mg/dl, median (IQR)

913 (739–1133)

843 (557–1200)

1.00 (1.00–1.00)

0.569

IgA level in mg/dl, median (IQR)

115 (55–251)

88 (56–161)

1.01 (0.99–1.02)

0.323

IgM level in mg/dl, median (IQR)

72 (45–123)

97 (68–124)

1.00 (0.98–1.00)

0.459

NT titer pretransplant patient, median (IQR)

90 (60.3–280)

135 (40–640)

1.00 (0.99–1.00)

0.518

NT titer pretransplant donor, median (IQR)

160 (67–190)

160 (40–160)

1.00 (0.99–1.00)

0.380

NT titer baseline patient, median (IQR)

80.5 (19.5–129.5)

40 (10–60)

1.00 (0.99–1.02)

0.192

  1. AML acute myeloid leukemia, CD4+CD45RO+ cells memory CD4+ cells, CD4+CD45RA+ cells naive CD4+ cells, EBMT European Group for Blood and Marrow Transplantation, GvHD graft-versus-host disease, NT neutralization titer.
  2. aAntibody response was defined by an NT titer of ≥10 and at least a twofold increase of titer from baseline (or titer above the highest level of measurement).
  3. bT cell reconstitution = normal CD4+ and CD8+ cell counts.
Back to article page